{"analyses":[{"ciLowerLimit":"0.99","ciPctValue":"95","ciUpperLimit":"2.11","estimateComment":"Obtained from a Cox proportional hazards model with treatment group as the independent variable \\[placebo/sipuleucel-T\\].","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.052","paramType":"Hazard Ratio (HR)","paramValue":"1.45","statisticalMethod":"Log Rank","testedNonInferiority":false},{"ciLowerLimit":"0.47","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.01","estimateComment":"Obtained from a Cox proportional hazards model with treatment group as the independent variable \\[sipuleucel-T/placebo\\]","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.052","paramType":"Hazard Ratio (HR)","paramValue":"0.69","statisticalMethod":"Log Rank","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.1","upperLimit":"16.6","value":"11.7"},{"groupId":"OG001","lowerLimit":"8.7","upperLimit":"13.1","value":"10.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"45"}],"units":"Participants"}],"description":"The time to objective disease progression in patients with asymptomatic metastatic hormone-refractory prostate cancer treated with APC8015 (sipuleucel-T).","dispersionType":"95% Confidence Interval","groups":[{"description":"All subjects randomized to receive sipuleucel-T.","id":"OG000","title":"Sipuleucel-T"},{"description":"All subjects randomized to receive placebo","id":"OG001","title":"Placebo"}],"paramType":"MEDIAN","populationDescription":"all randomized participants","reportingStatus":"POSTED","timeFrame":"36 months from randomization","title":"Time to Objective Disease Progression","type":"PRIMARY","unitOfMeasure":"Weeks"}